sellWeak cluster of 210b5-1 plan
Russell Alan J sold $2.7M of EWTX
Chief Scientific Officer at Edgewise Therapeutics, Inc.. 100,000 shares at an average of $27.37, traded Dec 30, 2024, filed Dec 31, 2024.
Warning score
33Value
$2.7M
100,000 shares
Holdings after
14,863
-87% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001562180-24-008663, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 30, 2024 | MOption exercise Common Stock10b5-1 | +100,000 | $0.18 | $18k | 114,863 | Dec 31, 2024 |
| Dec 30, 2024 | SOpen-market sale Common Stock10b5-1 | -100,000 | $27.37 | $2.7M | 14,863 | Dec 31, 2024 |
| Dec 30, 2024 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -100,000 | $0.00 | $0 | 1,356,780 | Dec 31, 2024 |
Related signals
Other insiders at Edgewise Therapeutics, Inc. and this insider’s other filings.
| Score | Side | Company | Insider | Value | Shares | Filed |
|---|---|---|---|---|---|---|
| 31Weak | sell 210b5-1 | EWTX Edgewise Therapeutics, Inc. | Semigran Marc Chief Development Officer | $882k | 29,709 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.